Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16121688rdf:typepubmed:Citationlld:pubmed
pubmed-article:16121688lifeskim:mentionsumls-concept:C0019693lld:lifeskim
pubmed-article:16121688lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16121688lifeskim:mentionsumls-concept:C0037949lld:lifeskim
pubmed-article:16121688lifeskim:mentionsumls-concept:C0028630lld:lifeskim
pubmed-article:16121688lifeskim:mentionsumls-concept:C0028621lld:lifeskim
pubmed-article:16121688pubmed:issue8lld:pubmed
pubmed-article:16121688pubmed:dateCreated2005-8-26lld:pubmed
pubmed-article:16121688pubmed:abstractTextNucleoside/nucleotide analogs (NAs) are essential components of most current antiretroviral regimens. Although many dual NA combinations may be used as backbones, not all display optimal results. For instance, some associations should be avoided due to antagonism (eg, zidovudine plus stavudine), high rates of toxicity (eg, didanosine plus stavudine) and/or increased risk of virological failure (eg, didanosine plus tenofovir). Moreover, the knowledge of plasma and intracellular interactions between different NAs is important for choosing appropriate combinations and optimal doses in order to optimize antiviral efficacy and minimize toxicities.lld:pubmed
pubmed-article:16121688pubmed:languageenglld:pubmed
pubmed-article:16121688pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16121688pubmed:citationSubsetIMlld:pubmed
pubmed-article:16121688pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16121688pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16121688pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16121688pubmed:statusMEDLINElld:pubmed
pubmed-article:16121688pubmed:monthAuglld:pubmed
pubmed-article:16121688pubmed:issn1472-4472lld:pubmed
pubmed-article:16121688pubmed:authorpubmed-author:BarreiroPablo...lld:pubmed
pubmed-article:16121688pubmed:authorpubmed-author:SorianoVincen...lld:pubmed
pubmed-article:16121688pubmed:authorpubmed-author:Jiménez-Náche...lld:pubmed
pubmed-article:16121688pubmed:authorpubmed-author:García-Benaya...lld:pubmed
pubmed-article:16121688pubmed:authorpubmed-author:GarcíaBenitoBlld:pubmed
pubmed-article:16121688pubmed:authorpubmed-author:RivasPabloPlld:pubmed
pubmed-article:16121688pubmed:issnTypePrintlld:pubmed
pubmed-article:16121688pubmed:volume6lld:pubmed
pubmed-article:16121688pubmed:ownerNLMlld:pubmed
pubmed-article:16121688pubmed:authorsCompleteYlld:pubmed
pubmed-article:16121688pubmed:pagination812-22lld:pubmed
pubmed-article:16121688pubmed:meshHeadingpubmed-meshheading:16121688...lld:pubmed
pubmed-article:16121688pubmed:meshHeadingpubmed-meshheading:16121688...lld:pubmed
pubmed-article:16121688pubmed:meshHeadingpubmed-meshheading:16121688...lld:pubmed
pubmed-article:16121688pubmed:meshHeadingpubmed-meshheading:16121688...lld:pubmed
pubmed-article:16121688pubmed:meshHeadingpubmed-meshheading:16121688...lld:pubmed
pubmed-article:16121688pubmed:meshHeadingpubmed-meshheading:16121688...lld:pubmed
pubmed-article:16121688pubmed:meshHeadingpubmed-meshheading:16121688...lld:pubmed
pubmed-article:16121688pubmed:year2005lld:pubmed
pubmed-article:16121688pubmed:articleTitleNucleoside/nucleotide backbones for the treatment of HIV infection.lld:pubmed
pubmed-article:16121688pubmed:affiliationService of Infectious Diseases and Service of Pharmacy, Hospital Carlos III, Madrid 28029, Spain.lld:pubmed
pubmed-article:16121688pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16121688pubmed:publicationTypeReviewlld:pubmed